While one open-label randomized trial and a combined analysis of 31 randomized controlled trials (mostly of 6-month duration) found no difference in cancer occurrence between insulin glargine and comparative groups (mostly neutral protamine Hagedorn insulin) [4], [5], observational studies analyzing large electronic healthcare databases or diabetes registry showed conflicting results [6]–[10]. The gene discussed is INS; the disease is cancer.